Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas.
| Revenue (Most Recent Fiscal Year) | $2.07B |
| Net Income (Most Recent Fiscal Year) | $418.30M |
| PE Ratio (Current Year Earnings Estimate) | 67.67 |
| PE Ratio (Trailing 12 Months) | 73.57 |
| PEG Ratio (Long Term Growth Estimate) | 2.60 |
| Price to Sales Ratio (Trailing 12 Months) | 9.31 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 15.01 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 70.31 |
| Pre-Tax Margin (Trailing 12 Months) | 11.47% |
| Net Margin (Trailing 12 Months) | 10.01% |
| Return on Equity (Trailing 12 Months) | 23.78% |
| Return on Assets (Trailing 12 Months) | 9.30% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.81 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.64 |
| Inventory Turnover (Trailing 12 Months) | 1.57 |
| Book Value per Share (Most Recent Fiscal Quarter) | $17.27 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.17 |
| Earnings per Share (Most Recent Fiscal Year) | $3.24 |
| Diluted Earnings per Share (Trailing 12 Months) | $3.29 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 70.39M |
| Free Float | 70.12M |
| Market Capitalization | $21.96B |
| Average Volume (Last 20 Days) | 0.45M |
| Beta (Past 60 Months) | 1.40 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.39% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |